The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Three-year follow-up of a Phase Ib trial of mosunetuzumab plus polatuzumab vedotin in R/R DLBCL
Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, comments on the three-year follow-up of a Phase Ib study (NCT03671018) of fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Kamdar reports that this combination continues to demonstrate durable responses at the follow-up. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
